East African Medical Journal

Log in or Register to get access to full text downloads.

Remember me or Register

DOWNLOAD FULL TEXT Open Access  DOWNLOAD FULL TEXT Subscription or Fee Access

Imatinib mesylate in chronic myelogenous leukemia: a Congolese experience

L.O. Ngolet, I Kocko, F.O. Galibaatipo Tsiba, J.D. Guelongo Okouango Ova, A Elira Dokekias


Background: Chronic myeloid leukemia is a clonal myeloproliferative disorder caused by reciprocal translocation t(9;22) that induces tyrosin kinase protein. Imatinib is a selective inhibitor of this protein.

Objectives: To assess responses to imatinib and outcome of Congolese patients with chronic phase chronic myeloid leukemia.

Design: retrospective study.

Settings: Clinical Haematology unit of Teaching Hospital in Brazzaville, Congo

Subjects: Newly diagnosed patients with chronic phase chronic myeloid leukemia treated with imatinib.

Results: A total of 25 males and 14 females with a mean age of 36 years at time of the diagnosis were enrolled in the study. The mean duration of the illness was 11.4 months. Imatinib induced complete hematologic response at 3 months in 100%. Major cytogenetic response was noticed in 87.18%. After a median follow up of 12 months, chronic myeloid leukemia had not progressed to the accelerated or blastic phase in an estimated 91.8% of patients and 86.6% were alive.

Conclusion: Imatinib is effective in newly chronic phase chronic myeloid leukemia patient even though cytogenetic response rate are lower in Africa than western countries populations

AJOL African Journals Online